LIX1L

Across TCGA pan-cancer cohorts, LIX1L Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LIX1L data layer compared with 20 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher LIX1L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LIX1L expression acts as an unfavorable survival marker.

CESC, LIHC, and SKCM are the cancer types where LIX1L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	III,IV	0.095	0.755	<.001	28	view →
LIHC	DFS	Median	All	0.081	0.543	.006	18	view →
SKCM	OS	Median	All	0.365	0.785	.001	18	view →
LUAD	DFS	Median	All	0.296	0.667	.009	9	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

LIX1L–CESC (OS)

Open the CESC breakdown →